Clarification: Amylin FDA information request story

Clarification: Amylin FDA info request story

SAN DIEGO – In a story March 15, The Associated Press reported that Bydureon is the proposed trade name of exenatide, a diabetes treatment being developed by Amylin Pharmaceuticals Inc., Eli Lilly & Co. and Alkermes Inc. The story should have specified that the once-weekly form of the drug, exenatide … Original article on : Clarification: Amylin FDA information request story.